How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program

Sanjiv J. Shah, Rebecca Cogswell, John J. Ryan, Kavita Sharma

Research output: Contribution to journalReview article

Abstract

Heart failure with preserved ejection fraction (HFpEF), a highly prevalent and complex clinical syndrome with high morbidity and mortality, is often unrecognized and not optimally treated. Clinical trials for HFpEF have been plagued by low enrollment, and clinicians often approach HFpEF patients with “therapeutic nihilism” given the perceived lack of available therapies based on the disappointing results of these prior trials. Due to these challenges, we have pioneered the successful creation of dedicated, specialized HFpEF clinical programs. Here, we discuss (1) the rationale for the development of a specialized HFpEF clinical program; (2) strategies for the systematic identification of HFpEF patients; (3) a standardized diagnostic and therapeutic approach; (4) validation of the HFpEF clinical program paradigm; (5) staffing and reimbursement considerations; (6) HFpEF clinical trial enrollment; and (7) challenges and future directions for HFpEF clinical programs. We conclude that it is feasible to create HFpEF clinical programs that fulfill the major unmet need of identifying and caring for patients with HFpEF. These clinics are essential for confirming the HFpEF diagnosis, providing standardized treatment, and facilitating clinical trial enrollment. It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients.

Original languageEnglish (US)
Article number122
JournalCurrent Cardiology Reports
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Heart Failure
Clinical Trials
Hope
Therapeutics
Patient Care
Morbidity
Mortality

Keywords

  • Clinical trials
  • Diagnosis
  • Disease management program
  • Heart failure with preserved ejection fraction
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. / Shah, Sanjiv J.; Cogswell, Rebecca; Ryan, John J.; Sharma, Kavita.

In: Current Cardiology Reports, Vol. 18, No. 12, 122, 01.12.2016.

Research output: Contribution to journalReview article

@article{7b883354c6d14d0392bf460a7c4fe16c,
title = "How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program",
abstract = "Heart failure with preserved ejection fraction (HFpEF), a highly prevalent and complex clinical syndrome with high morbidity and mortality, is often unrecognized and not optimally treated. Clinical trials for HFpEF have been plagued by low enrollment, and clinicians often approach HFpEF patients with “therapeutic nihilism” given the perceived lack of available therapies based on the disappointing results of these prior trials. Due to these challenges, we have pioneered the successful creation of dedicated, specialized HFpEF clinical programs. Here, we discuss (1) the rationale for the development of a specialized HFpEF clinical program; (2) strategies for the systematic identification of HFpEF patients; (3) a standardized diagnostic and therapeutic approach; (4) validation of the HFpEF clinical program paradigm; (5) staffing and reimbursement considerations; (6) HFpEF clinical trial enrollment; and (7) challenges and future directions for HFpEF clinical programs. We conclude that it is feasible to create HFpEF clinical programs that fulfill the major unmet need of identifying and caring for patients with HFpEF. These clinics are essential for confirming the HFpEF diagnosis, providing standardized treatment, and facilitating clinical trial enrollment. It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients.",
keywords = "Clinical trials, Diagnosis, Disease management program, Heart failure with preserved ejection fraction, Treatment",
author = "Shah, {Sanjiv J.} and Rebecca Cogswell and Ryan, {John J.} and Kavita Sharma",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s11886-016-0802-1",
language = "English (US)",
volume = "18",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program

AU - Shah, Sanjiv J.

AU - Cogswell, Rebecca

AU - Ryan, John J.

AU - Sharma, Kavita

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Heart failure with preserved ejection fraction (HFpEF), a highly prevalent and complex clinical syndrome with high morbidity and mortality, is often unrecognized and not optimally treated. Clinical trials for HFpEF have been plagued by low enrollment, and clinicians often approach HFpEF patients with “therapeutic nihilism” given the perceived lack of available therapies based on the disappointing results of these prior trials. Due to these challenges, we have pioneered the successful creation of dedicated, specialized HFpEF clinical programs. Here, we discuss (1) the rationale for the development of a specialized HFpEF clinical program; (2) strategies for the systematic identification of HFpEF patients; (3) a standardized diagnostic and therapeutic approach; (4) validation of the HFpEF clinical program paradigm; (5) staffing and reimbursement considerations; (6) HFpEF clinical trial enrollment; and (7) challenges and future directions for HFpEF clinical programs. We conclude that it is feasible to create HFpEF clinical programs that fulfill the major unmet need of identifying and caring for patients with HFpEF. These clinics are essential for confirming the HFpEF diagnosis, providing standardized treatment, and facilitating clinical trial enrollment. It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients.

AB - Heart failure with preserved ejection fraction (HFpEF), a highly prevalent and complex clinical syndrome with high morbidity and mortality, is often unrecognized and not optimally treated. Clinical trials for HFpEF have been plagued by low enrollment, and clinicians often approach HFpEF patients with “therapeutic nihilism” given the perceived lack of available therapies based on the disappointing results of these prior trials. Due to these challenges, we have pioneered the successful creation of dedicated, specialized HFpEF clinical programs. Here, we discuss (1) the rationale for the development of a specialized HFpEF clinical program; (2) strategies for the systematic identification of HFpEF patients; (3) a standardized diagnostic and therapeutic approach; (4) validation of the HFpEF clinical program paradigm; (5) staffing and reimbursement considerations; (6) HFpEF clinical trial enrollment; and (7) challenges and future directions for HFpEF clinical programs. We conclude that it is feasible to create HFpEF clinical programs that fulfill the major unmet need of identifying and caring for patients with HFpEF. These clinics are essential for confirming the HFpEF diagnosis, providing standardized treatment, and facilitating clinical trial enrollment. It is our hope that the information provided here will encourage others to establish their own specialized HFpEF programs, thereby allowing for comprehensive care for these complex patients.

KW - Clinical trials

KW - Diagnosis

KW - Disease management program

KW - Heart failure with preserved ejection fraction

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84993982768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993982768&partnerID=8YFLogxK

U2 - 10.1007/s11886-016-0802-1

DO - 10.1007/s11886-016-0802-1

M3 - Review article

VL - 18

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 12

M1 - 122

ER -